TISIDB

Summary
Symbol	MUC1
Name	mucin 1, cell surface associated
Aliases	CD227; PEM; ADMCKD; ADMCKD1; MCKD; MCKD1; mucin 1, transmembrane; medullary cystic kidney disease 1 (autosom ......
Chromosomal Location	1q22
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Apical cell membrane Single-pass type I membrane protein Note=Exclusively located in the apical domain of the plasma membrane of highly polarized epithelial cells. After endocytosis, internalized and recycled to the cell membrane. Located to microvilli and to the tips of long filopodial protusions.; SUBCELLULAR LOCATION: Isoform 5: Secreted.; SUBCELLULAR LOCATION: Isoform Y: Secreted.; SUBCELLULAR LOCATION: Isoform 9: Secreted.; SUBCELLULAR LOCATION: Mucin-1 subunit beta: Cell membrane. Cytoplasm. Nucleus. Note=On EGF and PDGFRB stimulation, transported to the nucleus through interaction with CTNNB1, a process which is stimulated by phosphorylation. On HRG stimulation, colocalizes with JUP/gamma-catenin at the nucleus.
Domain	PF01390 SEA domain
Function	The alpha subunit has cell adhesive properties. Can act both as an adhesion and an anti-adhesion protein. May provide a protective layer on epithelial cells against bacterial and enzyme attack.; FUNCTION: The beta subunit contains a C-terminal domain which is involved in cell signaling, through phosphorylations and protein-protein interactions. Modulates signaling in ERK, SRC and NF-kappa-B pathways. In activated T-cells, influences directly or indirectly the Ras/MAPK pathway. Promotes tumor progression. Regulates TP53-mediated transcription and determines cell fate in the genotoxic stress response. Binds, together with KLF4, the PE21 promoter element of TP53 and represses TP53 activity.

> Gene Ontology [ TOP ]
Biological Process	GO:0000075 cell cycle checkpoint GO:0000077 DNA damage checkpoint GO:0000082 G1/S transition of mitotic cell cycle GO:0006473 protein acetylation GO:0006475 internal protein amino acid acetylation GO:0006486 protein glycosylation GO:0006493 protein O-linked glycosylation GO:0006977 DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest GO:0006978 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0007050 cell cycle arrest GO:0007093 mitotic cell cycle checkpoint GO:0007162 negative regulation of cell adhesion GO:0007346 regulation of mitotic cell cycle GO:0008630 intrinsic apoptotic signaling pathway in response to DNA damage GO:0009100 glycoprotein metabolic process GO:0009101 glycoprotein biosynthetic process GO:0010944 negative regulation of transcription by competitive promoter binding GO:0010948 negative regulation of cell cycle process GO:0016266 O-glycan processing GO:0016570 histone modification GO:0016573 histone acetylation GO:0018205 peptidyl-lysine modification GO:0018393 internal peptidyl-lysine acetylation GO:0018394 peptidyl-lysine acetylation GO:0030330 DNA damage response, signal transduction by p53 class mediator GO:0031056 regulation of histone modification GO:0031058 positive regulation of histone modification GO:0031570 DNA integrity checkpoint GO:0031571 mitotic G1 DNA damage checkpoint GO:0033627 cell adhesion mediated by integrin GO:0033628 regulation of cell adhesion mediated by integrin GO:0033629 negative regulation of cell adhesion mediated by integrin GO:0035065 regulation of histone acetylation GO:0035066 positive regulation of histone acetylation GO:0036003 positive regulation of transcription from RNA polymerase II promoter in response to stress GO:0042770 signal transduction in response to DNA damage GO:0042771 intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator GO:0042772 DNA damage response, signal transduction resulting in transcription GO:0043413 macromolecule glycosylation GO:0043543 protein acylation GO:0043618 regulation of transcription from RNA polymerase II promoter in response to stress GO:0043620 regulation of DNA-templated transcription in response to stress GO:0043967 histone H4 acetylation GO:0044770 cell cycle phase transition GO:0044772 mitotic cell cycle phase transition GO:0044773 mitotic DNA damage checkpoint GO:0044774 mitotic DNA integrity checkpoint GO:0044783 G1 DNA damage checkpoint GO:0044819 mitotic G1/S transition checkpoint GO:0044843 cell cycle G1/S phase transition GO:0045786 negative regulation of cell cycle GO:0045787 positive regulation of cell cycle GO:0045930 negative regulation of mitotic cell cycle GO:0070085 glycosylation GO:0071156 regulation of cell cycle arrest GO:0071158 positive regulation of cell cycle arrest GO:0072331 signal transduction by p53 class mediator GO:0072332 intrinsic apoptotic signaling pathway by p53 class mediator GO:0072395 signal transduction involved in cell cycle checkpoint GO:0072401 signal transduction involved in DNA integrity checkpoint GO:0072413 signal transduction involved in mitotic cell cycle checkpoint GO:0072422 signal transduction involved in DNA damage checkpoint GO:0072431 signal transduction involved in mitotic G1 DNA damage checkpoint GO:0090068 positive regulation of cell cycle process GO:0090239 regulation of histone H4 acetylation GO:0090240 positive regulation of histone H4 acetylation GO:0097193 intrinsic apoptotic signaling pathway GO:1901796 regulation of signal transduction by p53 class mediator GO:1901797 negative regulation of signal transduction by p53 class mediator GO:1901983 regulation of protein acetylation GO:1901985 positive regulation of protein acetylation GO:1901987 regulation of cell cycle phase transition GO:1901988 negative regulation of cell cycle phase transition GO:1901990 regulation of mitotic cell cycle phase transition GO:1901991 negative regulation of mitotic cell cycle phase transition GO:1902165 regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator GO:1902166 negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator GO:1902229 regulation of intrinsic apoptotic signaling pathway in response to DNA damage GO:1902230 negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage GO:1902253 regulation of intrinsic apoptotic signaling pathway by p53 class mediator GO:1902254 negative regulation of intrinsic apoptotic signaling pathway by p53 class mediator GO:1902275 regulation of chromatin organization GO:1902400 intracellular signal transduction involved in G1 DNA damage checkpoint GO:1902402 signal transduction involved in mitotic DNA damage checkpoint GO:1902403 signal transduction involved in mitotic DNA integrity checkpoint GO:1902532 negative regulation of intracellular signal transduction GO:1902806 regulation of cell cycle G1/S phase transition GO:1902807 negative regulation of cell cycle G1/S phase transition GO:1905269 positive regulation of chromatin organization GO:2000045 regulation of G1/S transition of mitotic cell cycle GO:2000134 negative regulation of G1/S transition of mitotic cell cycle GO:2000756 regulation of peptidyl-lysine acetylation GO:2000758 positive regulation of peptidyl-lysine acetylation GO:2001020 regulation of response to DNA damage stimulus GO:2001021 negative regulation of response to DNA damage stimulus GO:2001233 regulation of apoptotic signaling pathway GO:2001234 negative regulation of apoptotic signaling pathway GO:2001242 regulation of intrinsic apoptotic signaling pathway GO:2001243 negative regulation of intrinsic apoptotic signaling pathway
Molecular Function	GO:0000978 RNA polymerase II core promoter proximal region sequence-specific DNA binding GO:0000987 core promoter proximal region sequence-specific DNA binding GO:0001159 core promoter proximal region DNA binding GO:0002039 p53 binding
Cellular Component	GO:0000785 chromatin GO:0000790 nuclear chromatin GO:0005796 Golgi lumen GO:0016324 apical plasma membrane GO:0044454 nuclear chromosome part GO:0045177 apical part of cell

> KEGG and Reactome Pathway [ TOP ]
KEGG	-
Reactome	R-HSA-5621481: C-type lectin receptors (CLRs) R-HSA-1280215: Cytokine Signaling in Immune system R-HSA-5621480: Dectin-2 family R-HSA-5083632: Defective C1GALT1C1 causes Tn polyagglutination syndrome (TNPS) R-HSA-5083636: Defective GALNT12 causes colorectal cancer 1 (CRCS1) R-HSA-5083625: Defective GALNT3 causes familial hyperphosphatemic tumoral calcinosis (HFTC) R-HSA-1643685: Disease R-HSA-3906995: Diseases associated with O-glycosylation of proteins R-HSA-3781865: Diseases of glycosylation R-HSA-168256: Immune System R-HSA-168249: Innate Immune System R-HSA-6785807: Interleukin-4 and 13 signaling R-HSA-392499: Metabolism of proteins R-HSA-5173105: O-linked glycosylation R-HSA-913709: O-linked glycosylation of mucins R-HSA-597592: Post-translational protein modification R-HSA-449147: Signaling by Interleukins R-HSA-977068: Termination of O-glycan biosynthesis

> KEGG and Reactome Pathway

[ TOP ]

KEGG

Reactome

R-HSA-5621481: C-type lectin receptors (CLRs)
R-HSA-1280215: Cytokine Signaling in Immune system
R-HSA-5621480: Dectin-2 family
R-HSA-5083632: Defective C1GALT1C1 causes Tn polyagglutination syndrome (TNPS)
R-HSA-5083636: Defective GALNT12 causes colorectal cancer 1 (CRCS1)
R-HSA-5083625: Defective GALNT3 causes familial hyperphosphatemic tumoral calcinosis (HFTC)
R-HSA-1643685: Disease
R-HSA-3906995: Diseases associated with O-glycosylation of proteins
R-HSA-3781865: Diseases of glycosylation
R-HSA-168256: Immune System
R-HSA-168249: Innate Immune System
R-HSA-6785807: Interleukin-4 and 13 signaling
R-HSA-392499: Metabolism of proteins
R-HSA-5173105: O-linked glycosylation
R-HSA-913709: O-linked glycosylation of mucins
R-HSA-597592: Post-translational protein modification
R-HSA-449147: Signaling by Interleukins
R-HSA-977068: Termination of O-glycan biosynthesis

Summary
Symbol	MUC1
Name	mucin 1, cell surface associated
Aliases	CD227; PEM; ADMCKD; ADMCKD1; MCKD; MCKD1; mucin 1, transmembrane; medullary cystic kidney disease 1 (autosom ......
Chromosomal Location	1q22
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between MUC1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining

[ TOP ]

Literatures describing the relation between MUC1 and anti-tumor immunity in human cancer.

PMID	Cancer type	Relation to immunity	Evidence sentences
28126925	Acute Myeloid Leukemia	Inhibit immunity (T cell function)	MUC1 induces increased expression of c-myc in EVs that induces proliferation in the target MDSC population via downstream effects on cell cycle proteins.
27604597	Prostate carcinoma	Promote immunity (T cell function); essential for immunotherapy	In conclusion, vaccination with Tn-MUC1-loaded DCs in nmCRPC patients appears to be safe, able to induce significant T-cell responses, and have biological activity as measured by the increase in PSADT following vaccination.
29258739	Triple-Negative Breast Cancer	Promote immunity (T cell function); essential for immunotherapy	Combination Immunotherapy of MUC1 mRNA Nano-vaccine and CTLA-4 Blockade Effectively Inhibits Growth of Triple Negative Breast Cancer. In vivo studies demonstrated that the NP-based mRNA vaccine, targeted to mannose receptors on DCs, could successfully express tumor antigen in the DCs of the lymph node; that the NP vaccine could induce a strong, antigen-specific, in vivo cytotoxic T lymphocyte response against TNBC 4T1 cells; and that combination immunotherapy of the vaccine and anti-CTLA-4 monoclonal antibody could significantly enhance anti-tumor immune response compared to the vaccine or monoclonal antibody alone.
24605110	Pancreatic Carcinoma	Inhibit immunity; immunotherapy target	Pancreatic Cancer Cells Isolated from Muc1-Null Tumors Favor the Generation of a Mature Less Suppressive MDSC Population. This is the first report that clearly suggests a functional role of pancreatic tumor-associated MUC1 in the development of functional MDSCs.
29263152	Triple-negative breast carcinoma	Inhibit immunity (T cell function)	The immune checkpoint ligand PD-L1 and the transmembrane mucin MUC1 are upregulated in triple-negative breast cancer (TNBC), where they contribute to its aggressive pathogenesis. Here, we report that genetic or pharmacological targeting of the oncogenic MUC1 subunit MUC1-C is sufficient to suppress PD-L1 expression in TNBC cells. Mechanistic investigations showed that MUC1-C acted to elevate PD-L1 transcription by recruitment of MYC and NF-κB p65 to the PD-L1 promoter. In an immunocompetent model of TNBC in which Eo771/MUC1-C cells were engrafted into MUC1 transgenic mice, we showed that targeting MUC1-C associated with PD-L1 suppression, increases in tumor-infiltrating CD8+ T cells and tumor cell killing. MUC1 expression in TNBCs also correlated inversely with CD8, CD69, and GZMB, and downregulation of these markers associated with decreased survival.
16467101	Adenocarcinoma	Promote immunity (T cell function); essential for immunotherapy	Mannan-MUC1-pulsed dendritic cell immunotherapy: a phase I trial in patients with adenocarcinoma. Immunization produced T-cell responses in all patients with evidence of tumor stabilization in 2 of the 10 advanced cancer patients treated.
28288138	Non-Small Cell Lung Carcinoma	Inhibit immunity	The present studies demonstrate that MUC1-C activates PD-L1 expression in NSCLC cells. We show that MUC1-C increases NF-κB p65 occupancy on the CD274/PD-L1 promoter and thereby drives CD274 transcription. In concert with these results, targeting MUC1-C in NSCLC tumors suppresses PD-L1 and induces these effectors of innate and adaptive immunity. These findings support a previously unrecognized central role for MUC1-C in integrating PD-L1 activation with suppression of immune effectors and poor clinical outcome.
19196663	Lymphoma	Inhibit immunity	In addition to diminishing recruitment of MDSCs, the effect of MUC1/sec on MDSC-suppressive mechanisms was investigated. MUC1/sec, or its unique immunoenhancing peptide, is capable of blocking expression of arginase 1 and production of reactive oxygen species in MDSCs, implicated in the suppression of T cells.
24894093	lung carcinoma	Inhibit immunity	The goals of the present study were to define the effects of simultaneous cisplatin/tecemotide therapy on tumor development in a human mucin 1 (MUC1) transgenic lung cancer mouse model and to examine the effects of radiotherapy (RTX) on splenocytes, serum cytokines, and immune response to tecemotide.
29633523	carcinoma	Promote immunity	Synthetic vaccines based on MUC1 tandem repeat motifs, comprising tumor-associated 2,3-sialyl-T antigen, conjugated to the immunostimulating tetanus toxoid, are reported herein.
21540305	Pleural Malignant Mesothelioma	Inhibit immunity (T/NK cell function); immunotherapy target	Mucin (MUC)1, which is expressed and recognised by cytotoxic T-cells in numerous cancer types, has not been investigated as a potential immune target in MPM. Thus, MUC1 expression and antigen presentation by MPM cells may represent an attractive target for immunotherapeutic treatment of MPM despite its hyperglycosylated profile.
18661524	Ovarian Cancinoma	Immunotherapy target	Immunotherapy against MUC1 could be effective in the treatment of epithelial ovarian cancer.
18561323	Bladder Carcinoma	Immunotherapy target	Upregulated expression of complement inhibitory proteins on bladder cancer cells and anti-MUC1 antibody immune selection.
22964632	Ovarian Carcinoma	Inhibit immunity; Candidate for immunotherapy target	Mucin 1 (MUC1) glycoprotein is a tumor-associated antigen overexpressed in ovarian cancer cells, making it a potential target for immune therapy. Compared with the KrasPten mice with tumors, the MUC1KrasPten mice show increased loco-regional metastasis and augmented accumulation of CD4+Foxp3+ immune-suppressive regulatory T cells. Vaccination of MUC1KrasPten mice with type 1 polarized dendritic cells (DC1) loaded with a MUC1 peptide (DC1-MUC1) can circumvent tumor-mediated immune suppression in the host, activate multiple immune effector genes and effectively prolong survival.
18713982	Pancreatic Adenocarcinoma	Inhibit immunity	MUC1 enhances tumor progression and contributes toward immunosuppression in a mouse model of spontaneous pancreatic adenocarcinoma. MUC1, a membrane tethered mucin glycoprotein, is overexpressed and aberrantly glycosylated in >80% of human ductal pancreatic adenocarcinoma. Data shows that during pancreatic cancer progression, MUC1-mediated mechanisms enhance the onset and progression of the disease, which in turn regulate the immune responses.
17671159	Non-Small Cell Lung Carcinoma	Immunotherapy target	L-BLP25 is a peptide vaccine strategy that targets the exposed core peptide of MUC1. In preclinical studies, L-BLP25 induced a cellular immune response characterized by T-cell proliferation in response to MUC1 and production of IFN-gamma.
25168392	renal cell carcinoma	Promote immunity (T cell infiltration)	This was associated with an early detectable cellular immunity to MUC1 and comparatively more infiltration by CD8? T cells. CD8? T-cell infiltration was observed in various organs, including the kidneys, irrespective of the presence of tumor or the expression of MUC1 by MVA.

Summary
Symbol	MUC1
Name	mucin 1, cell surface associated
Aliases	CD227; PEM; ADMCKD; ADMCKD1; MCKD; MCKD1; mucin 1, transmembrane; medullary cystic kidney disease 1 (autosom ......
Chromosomal Location	1q22
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of MUC1 in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	Second most enriched score: 0.54	Sensitive to T cell-mediated killing
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	MUC1
Name	mucin 1, cell surface associated
Aliases	CD227; PEM; ADMCKD; ADMCKD1; MCKD; MCKD1; mucin 1, transmembrane; medullary cystic kidney disease 1 (autosom ......
Chromosomal Location	1q22
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of MUC1 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	-0.628	0.214
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	-1.81	0.092
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	0.228	0.812
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	1.397	0.0845
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	1.319	0.639
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	1.503	0.689
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	0.239	0.667
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	0.95	0.275
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	-0.579	0.542
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	1.315	0.528
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	0.832	0.795
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	0.541	0.0369

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of MUC1 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	0	0	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	7.4	0	7.4	0.0709
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	7.4	0	7.4	0.096
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	0	17.6	-17.6	0.0806
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	16.7	-16.7	0.429
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	0	18.2	-18.2	0.199
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	6.2	-6.2	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	11.1	-11.1	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	0	0	0	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	0	0	0	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	MUC1
Name	mucin 1, cell surface associated
Aliases	CD227; PEM; ADMCKD; ADMCKD1; MCKD; MCKD1; mucin 1, transmembrane; medullary cystic kidney disease 1 (autosom ......
Chromosomal Location	1q22
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of MUC1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	MUC1
Name	mucin 1, cell surface associated
Aliases	CD227; PEM; ADMCKD; ADMCKD1; MCKD; MCKD1; mucin 1, transmembrane; medullary cystic kidney disease 1 (autosom ......
Chromosomal Location	1q22
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of MUC1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by MUC1. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	MUC1
Name	mucin 1, cell surface associated
Aliases	CD227; PEM; ADMCKD; ADMCKD1; MCKD; MCKD1; mucin 1, transmembrane; medullary cystic kidney disease 1 (autosom ......
Chromosomal Location	1q22
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of MUC1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	MUC1
Name	mucin 1, cell surface associated
Aliases	CD227; PEM; ADMCKD; ADMCKD1; MCKD; MCKD1; mucin 1, transmembrane; medullary cystic kidney disease 1 (autosom ......
Chromosomal Location	1q22
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of MUC1 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	MUC1
Name	mucin 1, cell surface associated
Aliases	CD227; PEM; ADMCKD; ADMCKD1; MCKD; MCKD1; mucin 1, transmembrane; medullary cystic kidney disease 1 (autosom ......
Chromosomal Location	1q22
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between MUC1 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	MUC1
Name	mucin 1, cell surface associated
Aliases	CD227; PEM; ADMCKD; ADMCKD1; MCKD; MCKD1; mucin 1, transmembrane; medullary cystic kidney disease 1 (autosom ......
Chromosomal Location	1q22
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting MUC1 collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse MUC1